Axsome Therapeutics, Inc. (AXSM) earnings
AXSM earnings moved a median of +0.83% by the close. Quarterly and annual AXSM reports and results, each read against the price at its own news timestamp. Back to the AXSM overview →
29 measured AXSM earnings events.
Where these AXSM earnings landedvs 28 measured AXSM earnings reactions
| Middle 50% of AXSM earnings reactions | -1.07% to +2.33% |
|---|---|
| Median reaction (to close) | +0.83% |
| Measured reactions | 28 |
Point-in-time · zero look-ahead
Half of the 28 AXSM earnings events with a measured close landed between -1.07% and +2.33%; 64% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Axsome Therapeutics to Report Third Quarter 2026 Financial Results on November 2 | Press release | -0.31% | -0.59% | |
| Axsome Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update | Press release | -0.23% | — | |
| Axsome Therapeutics to Report Second Quarter 2026 Financial Results on August 10 | Press release | -0.19% | +2.73% | |
| Axsome Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update | Press release | +5.90% | +7.29% | |
| Form 10-Q Axsome Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | +1.33% | -0.86% | |
| Axsome Therapeutics to Report First Quarter 2026 Financial Results on May 4 | Press release | -1.65% | +0.69% | |
| Form 10-K Axsome Therapeutics, For: Dec 31 | SEC filing · Form 10-K | -2.55% | -2.74% | |
| Axsome Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update | Press release | +1.16% | +9.56% | |
| Form 10-Q Axsome Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | -0.33% | +0.69% | |
| Axsome Therapeutics to Report Third Quarter 2025 Financial Results on November 3 | Press release | -1.08% | -0.98% | |
| Axsome Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update | Press release | -3.19% | -1.35% | |
| Form 10-Q Axsome Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | -1.11% | -2.38% | |
| Axsome Therapeutics to Report Second Quarter 2025 Financial Results on August 4 | Press release | +1.83% | +3.16% | |
| Axsome Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update | Press release | +2.47% | +2.11% | |
| Form 10-Q Axsome Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | -0.14% | -3.11% | |
| Axsome Therapeutics to Report First Quarter 2025 Financial Results on May 5 | Press release | -0.50% | -4.75% | |
| Form 10-K Axsome Therapeutics, For: Dec 31 | SEC filing · Form 10-K | +0.21% | -1.44% | |
| Axsome Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update | Press release | -1.23% | +4.73% | |
| Form 10-Q Axsome Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | +3.95% | +3.42% | |
| Axsome Therapeutics to Report Third Quarter 2024 Financial Results on November 12 | Press release | +0.00% | +1.68% | |
| Axsome Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update | Press release | +2.39% | +13.60% | |
| Form 10-Q Axsome Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | +1.01% | +0.97% | |
| Axsome Therapeutics to Report Second Quarter 2024 Financial Results on August 5 | Press release | -0.69% | +0.68% | |
| Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update | Press release | -0.19% | +1.25% | |
| Form 10-Q Axsome Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | -0.44% | +1.80% | |
| Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6 | Press release | +0.44% | +0.37% | |
| Form 10-K Axsome Therapeutics, For: Dec 31 | SEC filing · Form 10-K | -0.27% | -2.08% | |
| Axsome Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update | Press release | +2.87% | +1.84% | |
| Form 10-Q Axsome Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | +1.50% | +2.20% |
Keep exploring
More AXSM: analyst actions → · SEC filings → · AXSM overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Rubius Therapeutics, Inc. (RUBY) | 392 | -0.32% | 45% |
| Arrowhead Pharmaceuticals, Inc. (ARWR) | 391 | +0.13% | 52% |
| RA PHARMACEUTICALS (RARX) | 391 | -0.04% | 45% |
| Checkpoint Therapeutics, Inc. (CKPT) | 389 | 0.00% | 49% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.